Quantcast

Latest Lilly Stories

2014-09-18 20:22:43

- Trulicity, a weekly glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated for adults with type 2 diabetes as an adjunct to diet and exercise INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Trulicity(TM) (dulaglutide), approved today by the U.S. Food and Drug Administration, is the latest Eli Lilly and Company (NYSE: LLY) treatment option for adults with type 2 diabetes. Trulicity is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2...

2014-09-18 08:26:01

-- Phase III RAINBOW Trial Data Published in The Lancet Oncology -- INDIANAPOLIS, Sept. 18, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that results of the global Phase III trial of ramucirumab (CYRAMZA(TM)) in combination with paclitaxel in patients with advanced gastric (stomach) cancer or gastroesophageal junction (GEJ) adenocarcinoma were published in the online version of The Lancet Oncology. In the trial, known as RAINBOW, the addition of ramucirumab to...

2014-09-16 12:29:51

Company announces a series of digital and employee initiatives honoring women INDIANAPOLIS, Sept. 16, 2014 /PRNewswire/ -- Working Mother magazine has named Eli Lilly and Company as one of its Working Mother 100 Best Companies 20 years in a row. In observance of the honor, Lilly is planning a series of digital and employee initiatives. Working Mother annually honors companies for outstanding leadership in establishing policies, programs and a corporate culture that supports working mothers,...

2014-09-16 08:29:21

INDIANAPOLIS, Sept. 16, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and AstraZeneca today announced an agreement to co-develop and commercialize AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for Alzheimer's disease. The progression of Alzheimer's disease is characterized by the accumulation of amyloid plaque in the brain. BACE is an enzyme associated with the development of beta-amyloid. Inhibiting BACE...

2014-09-12 08:25:08

-- Ramucirumab Plus FOLFIRI Improved Survival in Metastatic Colorectal Cancer following Progression on a Bevacizumab-Based Regimen -- INDIANAPOLIS, Sept. 12, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that the RAISE trial, a Phase III study of ramucirumab (CYRAMZA(TM)) in combination with chemotherapy in patients with metastatic colorectal cancer (mCRC), met its primary endpoint of overall survival. The global, randomized, double-blind study compared ramucirumab...

2014-09-10 23:02:38

Susan M. Lilly has been appointed CEO of the AKC Canine Health Foundation, a non-profit organization dedicated to funding research that helps prevent, treat, and cure canine disease. Raleigh, NC (PRWEB) September 10, 2014 Susan M. Lilly, Certified Fund Raising Professional (CFRE), has been appointed CEO of the AKC Canine Health Foundation (CHF). Founded in 1995, CHF is the leading organization devoted solely to canine health research, having funded more than $40 million in worthy...

2014-09-09 08:31:17

INDIANAPOLIS, Sept. 9, 2014 /PRNewswire/ -- Fifty abstracts designed to advance knowledge in diabetes science will be presented Sept. 15-19 by Eli Lilly and Company (NYSE: LLY) at the 50(th) European Association for the Study of Diabetes (EASD) Annual Meeting. Notably, the company is highlighting two of its late-stage products: basal insulin peglispro and once-weekly dulaglutide. Twenty-eight of the abstracts will be presented as part of the Boehringer Ingelheim-Lilly Diabetes Alliance. EASD...

2014-08-25 12:26:25

INDIANAPOLIS, Aug. 25, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) will participate in the Morgan Stanley 2014 Global Healthcare Conference at the Grand Hyatt in New York, NY, on Monday, September 8, 2014. Derica Rice, Lilly's Executive Vice President, Global Services and Chief Financial Officer, will participate in a fireside chat at 12:50 p.m. EDT. A live audio webcast will be available on the Webcasts & Presentations section of Lilly's Investor website at...

2014-08-18 20:21:55

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar(TM) (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. Basaglar is not recommended for the treatment of diabetic ketoacidosis. Basaglar is Eli Lilly and Company (NYSE: LLY) and...

2014-08-02 00:21:08

Third product from the BI-Lilly Diabetes alliance to be approved by FDA RIDGEFIELD, Conn., and INDIANAPOLIS, Aug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Jardiance® (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). JARDIANCE is not for people with type 1...


Word of the Day
omadhaun
  • A fool; a simpleton: a term of abuse common in Ireland and to a less extent in the Gaelic-speaking parts of Scotland.
This word is partly Irish in origin.